|
| |
| | ICAAC: Atazanavir Matches Efavirenz in Reducing Viral Loads in HIV-Infected Patients |
 | | In the intention-to-treat analysis, 70 percent of the atazanavir patients achieved an undetectable viral load using the 400-copy assay, compared with 64 percent of the patients who were treated with the efavirenz-based therapy. | | | In the as treated analysis, 81 percent of the patients on atazanavir achieved an undetectable viral load compared with 84 percent of the patients on efavirenz. | | | Atazanavir is an azapeptide in Phase III clinical development. |
|
http://www.pslgroup.com/dg/21F0EE.htm
|
|
| |
| | TAG: Position Paper on atazanavir (BMS-232623), brand name Reyataz® |
| | Atazanavir is being reviewed as a protease inhibitor (PI) for people with HIV starting their first treatment regimen with a PI. | | | Atazanavir: a summary of two pharmacokinetic drug interaction studies in healthy subjects. | | | Diltiazem, a calcium-channel blocker, is used to treat high blood pressure and to control chest pain (angina). |
|
http://www.aidsinfonyc.org/tag/tx/atazanavir.html
|
|
| |
| | atazanavir (oral) - [Medication] |
| | Atazanavir is not a cure for HIV or AIDS, and you can still transmit the virus to others during therapy with this medication. | | | Atazanavir is used in combination with other medicines to treat HIV/AIDS. | | | Other medicines may also interact with atazanavir, talk to your doctor before taking any other medicines during treatment with atazanavir. |
|
http://www.peacehealth.org/kbase/multum/d04882a1.htm
|
|
| |
| | CATIE Fact Sheet : Atazanavir (Reyataz) |
| | Atazanavir has been tested and used mostly in people who are new to anti-HIV drugs. | | | If atazanavir levels become too low, HIV can develop resistance to it or to other anti-HIV drugs that are taken with atazanavir and your future treatment options may be reduced. | | | Because it is a relatively new drug, the role of atazanavir, if any, in the lipodystrophy syndrome is not clear. |
|
http://www.catie.ca/facts.nsf/9a83231f2055bda9852566b90004b064/7ecc48b4e4e2ab3b85256e680052f9ca?OpenDocument
|
|
| |
| | MedlinePlus Drug Information: Atazanavir |
| | Atazanavir is used in combination with other medications to treat human immunodeficiency virus (HIV) in patients with or without acquired immunodeficiency syndrome (AIDS). | | | Atazanavir does not cure HIV and may not prevent you from developing HIV related illnesses. | | | Atazanavir is in a class of medications called HIV protease inhibitors. |
|
http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a603019.html
|
|
| |
| | Clinical Care Options for HIV - Atazanavir: final phase III results published |
| | Using a cut-off of 200 copies/mL, 62% in the atazanavir group and 58% in the efavirenz arm were undetectable in an intent-to-treat analysis (as treated, 70% and 75%, respectively). | | | Elevated bilirubin (a by-product of the breakdown of red blood cells) occurred more often in the atazanavir arm, and jaundice and scleral icterus (yellowing of the eyes) were significantly more common among atazanavir recipients (P <.05). | | | After 48 weeks, 70% of subjects receiving atazanavir and 64% in the efavirenz arm had HIV RNA levels below 400 copies/mL in an intent-to-treat analysis. |
|
http://clinicaloptions.com/hiv/news/news_NAM_319.asp
|
|
| |
| | Atazanavir (Reyataz) |
| | Although in these studies atazanavir resulted in virologic responses comparable to those obtained with previously licensed drugs, the response rates for all treatment arms were surprisingly low, and the efficacy of unboosted atazanavir in initial therapy remains unclear. | | | Atazanavir has been studied in both initial and salvage therapy. | | | The response rates in the atazanavir-ritonavir and lopinavir-ritonavir arms were significantly better than those in a third treatment arm, atazanavir-saquinavir + tenofovir + one nucleoside analogue. |
|
http://hivinsite.ucsf.edu/InSite.jsp?page=ar-03-07
|
|
| |
| | AEGiS-AmFAR: Atazanavir’s Debut - August 2003 |
| | Atazanavir does not stand out from the other protease inhibitors in terms of efficacy. | | | An interim analysis at 24 weeks found that atazanavir was less effective than Kaletra. | | | This study enrolled 229 volunteers with an average of three years prior HIV therapy. |
|
http://www.aegis.com/pubs/amfar/2003/AM030802.html
|
|
| |
| | Drug Information: Atazanavir (Systemic) (Print Version) |
| | Atazanavir will not keep you from spreading HIV to other people. | | | It is very important that your doctor check your progress at regular visits to make sure this medicine is working properly and to check for unwanted effects. | | | People who receive this medicine may continue to have other problems usually related to AIDS or HIV disease. |
|
http://www.nlm.nih.gov/medlineplus/print/druginfo/uspdi/500483.html
|
|
| |
| | ATAZANAVIR |
| | Inform your doctor and pharmacist of all prescribed and non-prescribed drugs you are taking. | | | You will still be able to pass HIV by sexual contact, by blood transfer or by sharing needles. | | | Please inform your physician or pharmacist if you are taking any of the above drugs so that an alternative drug may be selected. |
|
http://www.tthhivclinic.com/FactSheets/html/ATAZANAVIR.html
|
|
| |
| | Atazanavir Early Access Program |
| | Atazanavir can be provided in the EAP to patients who are failing their current antiretroviral therapy (defined as an HIV RNA level > 5000 copies/ml and have had an absolute CD4 count | | | Fewer than 1 percent of individuals studied have discontinued atazanavir for elevated bilirubin or jaundice. | | | An early access program (EAP) provides medicines to eligible patients in need of alternative therapy prior to the medicine's approval. |
|
http://www.natap.org/2002/september/093002_1.htm
|
|
| |
| | Review of New PI Atazanavir |
| | In clinical trials in antiretroviral (ARV)-naive patients, atazanavir had efficacy similar to that of efavirenz (Sustiva) or nelfinavir (Viracept). | | | The objective of the current study was to review the pharmacology, virology, pharmacokinetics, resistance profile, clinical efficacy, safety, and drug interactions of atazanavir (Reyataz). | | | In contrast to comparators, atazanavir did not negatively impact the lipid profile. |
|
http://www.hivandhepatitis.com/recent/protease/091304_f.html
|
|
| |
| | Clinical Care Options for HIV - Atazanavir vs Lopinavir: What Study 045 Tells Us |
| | For those patients who do develop scleral icterus or jaundice (in the current study, 3% and 6%, respectively), resolution is usually rapid upon discontinuation of the drug. | | | Pharmacokinetic interaction between tenofovir and atazanavir coadministered with ritonavir in healthy subjects. | | | International Congress on Drug Therapy in HIV Infection; November 14-18, 2004; Glasgow, United Kingdom. |
|
http://clinicalcareoptions.com/hiv/jopt/articles/article.asp?a=Johnson-AIDS-2005-05&page=commentary
|
|
| |
| | AIDS Fact Sheet: Atazanavir (Reyataz) |
| | Atazanavir, also called Reyataz?, is a drug used for antiviral therapy. | | | Sometimes, if your virus develops resistance to one drug, it will also have resistance to other antiviral drugs. | | | About 10% of patients using atazanavir got jaundice. |
|
http://www.aids.org/factSheets/447-Atazanavir-Reyataz.html
|
|
| |
| | atazanavir - HIV: health and medical information about HIV and AIDS |
| | Nevertheless, atazanavir does not prevent the transmission of HIV among individuals, and it does not cure HIV infections or AIDS. | | | Scientific experts advise HIV-infected mothers not to breast-feed because of the risk of transmitting HIV to the infant. | | | Viewers should consult their healthcare provider before combining any drugs with atazanavir. |
|
http://www.medicinenet.com/atazanavir/article.htm
|
|
| |
| | Formulary - Reyataz (Atazanavir) |
| | In the atazanavir treatment group, 67% (32%) of patients achieved response compared with 62% (37%) in the efavirenz group. | | | Response was defined as a maintained confirmed HIV RNA level of <400 copies/mL (<50 copies/mL). | | | Please send any technical comments or questions to our webmaster. |
|
http://www.formularyjournal.com/formulary/article/articleDetail.jsp?id=66784
|
|
| |
| | Antiretroviral drug - Wikipedia, the free encyclopedia |
| | Like Kaletra and Atazanavir, it is very potent and is effective in 'salvage' therapy for patients with some drug resistance. | | | Increasingly, it is being replaced by newer drugs that are more convenient to take and less likely to promote resistant virus, such as Kaletra or Atazanavir. | | | Atazanavir is the first PI approved for once-daily dosing, and also appears to be less likely to cause lipodystrophy and elevated cholesterol as side effects. |
|
http://en.wikipedia.org/wiki/Highly_active_antiretroviral_therapy
|
|
| |
| | The Body: Atazanavir (Reyataz) |
| | New warnings on drug-drug interactions are noted in the prescribing information for atazanavir | | | Cohen discusses starting antiretroviral therapy (tenofovir vs. d4T, efavirenz vs. nevirapine), new protease inhibitor information (atazanavir and fos-amprenavir, a.k.a. | | | Two studies presented at CROI 2004 find atazanavir has a better side-effect profile than most protease inhibitors |
|
http://www.thebody.com/treat/bms232632.html
|
|
| |
| | Aidsmap Atazanavir/ritonavir comparable to lopinavir/ritonavir in PI-experienced |
| | An analysis of response according to genotypic and phenotypic susceptibility scores similar to that performed in the TORO studies of T-20 would be a useful adjunct to any report on studies in heavily pre-treated patients. | | | Further information about the combination of atazanavir/ritonavir was presented this week at the Second International AIDS Society Conference on HIV Pathogenesis and Treatment in Paris, suggesting that even when boosted with ritonavir, atazanavir is more lipid friendly than lopinavir. | | | Overall, the incidence of grade 2-4 adverse events did not differ between the groups, but diarrhoea was more common among lopinavir-treated patients (13 cases vs 8 among all atazanavir treated patients), whilst jaundice affected only the atazanavir-treated patients (9 cases). |
|
http://www.aidsmap.com/en/news/30D8389E-950C-4AF4-83F7-A222AC5D479E.asp
|
|
| |
| | Resistance: Atazanavir, Atazanavir/rtv, and Kaletra--studies 043, 045 |
| | After 24 weeks the study was ammended to allow patients to change regimens to one of several options, but very few did. | | | Data on the outcome of studies has previously been presented through week 24. | | | Given the definitions of resistance used in this study there is insufficient information to define a genotypic cut-off that is clinically relevant for the relative loss of atazanavir effect. |
|
http://www.natap.org/2003/EACS/day1_2.htm
|
|
| |
| | Atazanavir and Acid in Real Life - AIDS Clinical Care |
| | atazanavir levels when this drug is coadministered with acid-reducing | | | of atazanavir and acid-reducing therapy does not necessarily | | | Atazanavir and Acid in Real Life - AIDS Clinical Care |
|
http://aids-clinical-care.highwire.org/cgi/content/full/2005/511/4
|
|
| |
| | Atazanavir: Answers and Questions - AIDS Clinical Care |
| | Atazanavir: Answers and Questions - AIDS Clinical Care | | | Published in AIDS Clinical Care March 1, 2003 | | | Results of a phase 2 clinical trial at 48 weeks (AI424-007): A dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. |
|
http://aids-clinical-care.highwire.org/cgi/content/full/2003/301/4
|
|
| |
| | Interactions Between Atazanavir/Ritonavir and Tenofovir in Heavily Pretreated HIV Patients |
| | The aim of the present study was to assess the pharmacokinetic behavior of atazanavir (Reyataz)-ritonavir (Norvir) when it is co-administered with tenofovir disoproxil fumarate DF (Viread) in HIV-infected patients. | | | The values of the pharmacokinetic parameters for atazanavir and ritonavir were measured before (day 14 [week 2]) and after (day 42 [week 6]) initiation of tenofovir DF and are reported for the 10 patients who completed the study. | | | Ongoing NRTIs were selected according to the reverse transcriptase genotype of the HIV isolates from each patient. |
|
http://www.hivandhepatitis.com/recent/inter/072804_e.html
|
|
| |
| | Atazanavir interactions with tenofovir :Levitra Talk |
| | “Co-administration with atazanavir has not been studied but may result in an increase in PDE5 inhibitor-associated adverse events, including hypotension [low blood pressure], visual changes, and priapism [long-lasting, painful erections]. | | | Patients receiving atazanavir and tenofovir should be monitored for tenofovir-associated adverse events. | | | Atazanavir without ritonavir should not be co-administered with tenofovir.” |
|
http://www.levitratalk.com/news/mar2004/news_atazanavir_interactions_with_tenofovir_25mar.html
|
|
| |
| | Extended-use atazanavir controls HIV without inducing dyslipidemia |
| | Confirming past studies, atazanavir-treated patients showed "minimal changes" in lipid levels compared with baseline. | | | Atazanavir "may preclude the need to introduce the use of lipid-lowering agents to control PI-induced dyslipidemia in a significant proportion of patients," the investigators write. | | | In the paper they report efficacy and safety data of a median cumulative 108 weeks of extended atazanavir therapy in treatment-naïve as well as treated-experienced patients. |
|
http://www.aidsmeds.com/news/20040621clin007.html
|
|
| |
| | Atazanavir |
| | Complete and easy-to-read info on treating HIV and AIDS, including guided treatment lessons, info on drugs, recent news, community forums, a drug interactions checker, and "Graph My Labs". | | | Find results for atazanavir and anything else you are looking for instantly! | | | At eBay you can find practically anything, even atazanavir. |
|
http://haxwax-medications.com/Atazanavir.html
|
|
| |
| | References |
| | The 810 treatment-naive patients were stratified by HIV RNA level. | | | CONCLUSIONS:: For initial HIV treatment, a highly active antiretroviral therapy regimen of atazanavir/zidovudine/lamivudine is as efficacious and well tolerated as the combination of efavirenz/zidovudine/lamivudine. | | | Atazanavir-treated patients relative to comparator-treated patients did not demonstrate significant increases in total cholesterol, fasting low-density lipoprotein cholesterol, or fasting triglycerides over 48 weeks of therapy. |
|
http://hivinsite.ucsf.edu/InSite-KB-ref.jsp?page=ar-03-07&rf=3
|
|
| |
| | EACS: High Patient Adherence Rate Associated With Atazanavir |
| | Baseline adherence rates for 138 patients from Study 041 were 83% and 78% in the atazanavir and nelfinavir groups, respectively. | | | Study title: Atazanavir Is Associated With Better Patient Adherence: Long-Term Follow-Up Data from BMS 041 and 044 Studies. | | | WARSAW, POLAND -- October 31, 2003 -- HIV-infected patients may achieve better rates of adherence to their antiretroviral therapy by including atazanavir in their treatment regimen, according to results presented during the 9 |
|
http://www.docguide.com/dg.nsf/PrintPrint/5A711B97CDB91C5485256DD000510459
|
|
| |
| | Reyataz (atazanavir): a complete guide from AIDSmeds.com |
| | Atazanavir as effective as nelfinavir, but with less lipid effects (2/28/03) | | | Atazanavir and saquinavir helpful in patients failing HAART (6/30/03) | | | Atazanavir combination helpful in HIV treatment failure (5/30/05) |
|
http://www.aidsmeds.com/drugs/Reyataz.htm
|
|
| |
| | Protease inhibitors |
| | This class of drugs includes indinavir (Crixivan), ritonavir (Norvir), nelfinavir (Viracept), amprenavir (Agenerase), lopinavir plus ritonavir (Kaletra), saquinavir (Fortovase), and a new drug called atazanavir (Reyataz). | | | Reyataz received approval from the U.S. Food and Drug Administration (FDA) in mid-2003 and was the first protease inhibitor approved for once-daily dosing. |
|
http://www.healthatoz.com/healthatoz/Atoz/ency/protease_inhibitors.jsp
|
|
|
